Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Stephen M. Simes
AddedMar 19, 2024
UpdatedMay 31, 2026
Stephen M. Simes

Stephen M. Simes

Board Member, CytoDyn

LinkedIn

Stephen M. Simes's Career

CytoDyn
CytoDyn

Vancouver, WA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Stephen M. Simes's Career

CytoDyn
CytoDyn
Public$89.5M122002Vancouver, WA, US
Board Member· Board

Leadership at CytoDyn

Richard PestellRichard PestellBoard Member
Tanya Durkee UrbachTanya Durkee UrbachBoard Member
Karen J. BrunkeKaren J. BrunkeBoard Member
Nader Z. PourhassanNader Z. PourhassanBoard Member
Jordan NaydenovJordan NaydenovBoard Member
Greg GouldGreg GouldBoard Member

Similar to CytoDyn

Vir BiotechnologyVir BiotechnologySan Francisco, CA, USMedicines, Therapeuticsest. 2016Vir BiotechnologySan Francisco, CA, US · est. 2016

Vir Biotechnology, a clinical-stage firm, develops and commercializes treatments for viral and bacterial diseases in California.

Public · $908.6M576
CytoAgentsCytoAgentsPittsburgh, PA, USPharmaceuticalsest. 2018CytoAgentsPittsburgh, PA, US · est. 2018

CytoAgents: A clinical-stage biotech firm innovating treatments for life-threatening immune overreactions.

Series A · $17.2M15
ViriomViriomSan Diego, CA, USHBV Treatments, HIV Treatmentsest. 2009ViriomSan Diego, CA, US · est. 2009

Viriom: A therapeutic biotech firm innovating treatments for HIV and Hepatitis B.

Series B · $35.4M200
Gilead SciencesGilead SciencesFoster City, CA, USPharmaceuticals, Therapiesest. 1987Gilead SciencesFoster City, CA, US · est. 1987

Gilead Sciences: An American biopharmaceutical firm innovating therapies for critical diseases.

Public · $2B17k

Stephen M. Simes's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Stephen M. Simes

Dave LaurelloDave LaurelloBoard Member · Stratus TechnologiesDavid LaurelloDavid LaurelloCEO · Stratus TechnologiesMika MazorMika MazorCEO · Stratus HoldingsBret BoudousquieBret BoudousquieCEO · Stratus Medicaljaime patiño escobarjaime patiño escobarCEO at Stratos GroupKenny LauerKenny LauerBoard Member · Sxsw